Amorosa, V. K., Luetkemeyer, A., Kang, M., Johnson, V. A., Umbleja, T., Haas, D. W., . . . Peters, M. G. (2013). Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial.
Styl cytowania ChicagoAmorosa, Valerianna K., et al. Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. 2013.
Styl cytowania MLAAmorosa, Valerianna K., et al. Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. 2013.